Studies of Insulin Secretory Responses and of Arachidonic Acid Incorporation into Phospholipids of Stably Transfected Insulinoma Cells That Overexpress Group VIA Phospholipase A2 (iPLA2beta ) Indicate a Signaling Rather Than a Housekeeping Role for iPLA2beta *

Zhongmin Ma, Sasanka Ramanadham, Mary Wohltmann, Alan Bohrer, Fong-Fu Hsu, and John TurkDagger

From the Mass Spectrometry Resource, Division of Endocrinology, Diabetes, and Metabolism, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri 63110

Received for publication, November 16, 2000, and in revised form, January 2, 2001



    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

A cytosolic 84-kDa group VIA phospholipase A2 (iPLA2beta ) that does not require Ca2+ for catalysis has been cloned from several sources, including rat and human pancreatic islet beta -cells and murine P388D1 cells. Many potential iPLA2beta functions have been proposed, including a signaling role in beta -cell insulin secretion and a role in generating lysophosphatidylcholine acceptors for arachidonic acid incorporation into P388D1 cell phosphatidylcholine (PC). Proposals for iPLA2beta function rest in part on effects of inhibiting iPLA2beta activity with a bromoenol lactone (BEL) suicide substrate, but BEL also inhibits phosphatidate phosphohydrolase-1 and a group VIB phospholipase A2. Manipulation of iPLA2beta expression by molecular biologic means is an alternative approach to study iPLA2beta functions, and we have used a retroviral construct containing iPLA2beta cDNA to prepare two INS-1 insulinoma cell clonal lines that stably overexpress iPLA2beta . Compared with parental INS-1 cells or cells transfected with empty vector, both iPLA2beta -overexpressing lines exhibit amplified insulin secretory responses to glucose and cAMP-elevating agents, and BEL substantially attenuates stimulated secretion. Electrospray ionization mass spectrometric analyses of arachidonic acid incorporation into INS-1 cell PC indicate that neither overexpression nor inhibition of iPLA2beta affects the rate or extent of this process in INS-1 cells. Immunocytofluorescence studies with antibodies directed against iPLA2beta indicate that cAMP-elevating agents increase perinuclear fluorescence in INS-1 cells, suggesting that iPLA2beta associates with nuclei. These studies are more consistent with a signaling than with a housekeeping role for iPLA2beta in insulin-secreting beta -cells.



    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Phospholipases A2 (PLA2)1 catalyze hydrolysis of the sn-2 fatty acid substituent from glycerophospholipid substrates to yield a free fatty acid and a 2-lysophospholipid (1-7). PLA2 are a diverse group of enzymes, and the first members to be well characterized have low molecular masses (~14 kDa), require millimolar [Ca2+] for catalytic activity, and function as extracellular secreted enzymes designated sPLA2 (3, 6). The first PLA2 to be cloned that is active at [Ca2+] that can be achieved in the cytosol of living cells is an 85-kDa protein classified as a group IV PLA2 and designated cPLA2 (3, 5). This enzyme is induced to associate with its substrates in membranes by rises in cytosolic [Ca2+] within the range achieved in cells stimulated by extracellular signals that induce Ca2+ release from intracellular sequestration sites or Ca2+ entry from the extracellular space, is also regulated by phosphorylation, and prefers substrates with sn-2 arachidonoyl residues (5).

A second cytosolic PLA2 has been cloned (8-10) that does not require Ca2+ for catalysis, and it is classified as a group VIA PLA2 and has been designated iPLA2 (3, 4). The iPLA2 enzymes cloned from hamster (8), mouse (9), and rat (10) cells represent species homologs, and all are 84-kDa proteins containing 752 amino acid residues with highly homologous sequences. Each contains a GXSXG lipase consensus motif and eight stretches of a repeating motif homologous to a repetitive motif in the integral membrane protein-binding domain of ankyrin (8-10). Each of these iPLA2 enzymes is susceptible to inhibition (8-10) by a bromoenol lactone (BEL) suicide substrate (11, 12) that is not an effective inhibitor of sPLA2 or cPLA2 enzymes at comparable concentrations (4, 11-14). It has been proposed that this enzyme now be designated iPLA2beta to distinguish it from a membrane-associated, Ca2+-independent PLA2 that contains a peroxisomal targeting sequence and is designated iPLA2gamma (15, 16).

Proposed functions for iPLA2beta include a housekeeping role in phospholipid remodeling that involves generation of lysophospholipid acceptors for incorporation of arachidonic acid into phospholipids of murine P388D1 macrophage-like cells (4, 17, 18). This proposal (4) derives from experiments involving inhibition of iPLA2 activity in P388D1 cells with BEL (17) or with an antisense oligonucleotide (18). Inhibition of P388D1 cell iPLA2 activity suppresses incorporation of [3H]arachidonic acid into phospholipids and reduces [3H]lysophosphatidylcholine (LPC) levels in [3H]choline-labeled cells (17, 18). Arachidonate incorporation (17, 18) reflects a deacylation/reacylation cycle (19, 20) of phospholipid remodeling rather than de novo synthesis (21), and the level of LPC acceptors is thought to limit the rate of [3H]arachidonic acid incorporation into P388D1 cell phosphatidylcholine (PC) (17, 18).

Many other potential iPLA2beta functions have been proposed (22-54), and the facts that multiple splice variants are differentially expressed among cells and form hetero-oligomers with distinct properties suggest that iPLA2 gene products might have multiple functions (23, 31, 44, 45). Proposed iPLA2beta functions include signaling in secretion (10, 22, 25, 29, 48-50), and we and others (47-54) have found that, in pancreatic islets, BEL attenuates glucose-induced insulin secretion, arachidonate release, and rises in islet beta -cell cytosolic [Ca2+]. Both pancreatic islets and brain contain electrically active secretory cells that express high levels of iPLA2beta (10), and iPLA2beta is the vastly predominant brain cytosolic PLA2 (24, 34, 35). BEL also inhibits iPLA2gamma (15) and phosphatidate phosphohydrolase-1 (PAPH-1) (55), and the ambiguity of pharmacologic studies makes manipulating iPLA2beta expression by molecular biologic means an attractive alternative to study iPLA2beta functions. We report here the preparation of two stably transfected insulinoma cell lines that overexpress iPLA2beta . We have studied insulin secretory responses, arachidonate incorporation into phosphatidylcholine, and iPLA2beta subcellular location in these lines.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- ECL detection reagents and 1-palmitoyl-2-[14C]linoleoyl-sn-glycero-3-phosphocholine (55 mCi/mmol) were purchased from Amersham Pharmacia Biotech. Phosphatidylcholine standards were obtained from Avanti Polar Lipids (Birmingham, AL) and arachidonic acid from Nu-Chek Prep (Elysian, MN). BEL iPLA2 suicide substrate (E)-6-(bromomethylene)tetrahydro-3-(1-naphthalenyl)-2H-pyran-2-one was purchased from Cayman Chemical (Ann Arbor, MI). Tissue culture media (CMRL-1066, RPMI, and minimal essential medium), penicillin, streptomycin, Hanks' balanced salt solution, and L-glutamine were purchased from Life Technologies, Inc. Fetal bovine serum was obtained from HyClone (Logan, UT) and Pentex bovine serum albumin (BSA, fatty acid-free, fraction V) from ICN Biomedical (Aurora, OH). ATP, ampicillin, IBMX, propranolol, and kanamycin were obtained from Sigma and forskolin from Calbiochem (La Jolla, CA). Krebs-Ringer bicarbonate buffer (KRB) contained 25 mM HEPES, pH 7.4, 115 mM NaCl, 24 mM NaHCO3, 5 mM KCl, 1 mM MgCl2.

Cell Culture-- INS-1 insulinoma cells provided by Dr. Christopher Newgard (University of Texas, Dallas, TX) were cultured as described (56-58) in RPMI 1640 medium containing 11 mM glucose, 10% fetal calf serum, 10 mM Hepes buffer, 2 mM glutamine, 1 mM sodium pyruvate, 50 mM beta -mercaptoethanol, 100 units/ml penicillin, and 100 µg/ml streptomycin. RetroPack PT 67 cells (CLONTECH, Palo Alto, CA) were maintained in Dulbecco's modified Eagle's medium (4.5 mg/ml glucose) containing 10% fetal bovine serum, 4 mM L-glutamine, 100 units/ml penicillin, and 100 µg/ml streptomycin.

Preparation of Recombinant Retrovirus Containing the cDNA Encoding the Rat Pancreatic Islet iPLA2beta -- A retroviral system (59, 60) was used to stably transfect INS-1 cells with iPLA2beta cDNA and achieve overexpression. To construct the retroviral vector, iPLA2beta cDNA (10) was subcloned into EcoRI-BglII multiple cloning sites of pMSCVneo vector using the CLONTECH murine stem cell retrovirus (MSCV) expression system. Full-length rat pancreatic islet iPLA2beta cDNA was excised from pBK-CMV-iPLA2beta vector and subcloned into the retroviral vector pMSCVneo at the recognition sites for restriction endonucleases EcoRI and XhoI. The construct containing the iPLA2beta cDNA (pMSCVneo-iPLA2beta ) was transfected into CLONTECH RetroPack PT 67 packaging cells with a GenePORTER transfection system according to the manufacturer's instructions (Gene Therapy Systems, San Diego, CA). Upon transfection of packaging cells, pMSCVneo integrated into the genome and expressed a transcript containing viral packaging signal, a neomycin resistance gene that confers resistance to the selection agent G418, and iPLA2beta cDNA. This transcript is recognized by viral proteins in packaging cells. Introduction of pMSCVneo-iPLA2beta into PT 67 cells results in production of high titer, replication-incompetent infectious virus particles that were released into the culture medium, collected, and used to infect INS-1 cells.

Infection of INS-1 Cells with Recombinant Retroviral Particles and Selection of Stably Transfected Cells That Overexpress iPLA2beta -- INS-1 cells were plated on 100-mm Petri dishes at a density of 3-5 × 105 cells/plate 12-18 h before infection. Freshly collected, retrovirus-containing medium was passed through a 0.45-µm filter and added to INS-1 cell monolayers. Polybrene (final concentration 4 µg/ml) was added to culture medium, and medium was replaced after 24 h of incubation. To select stably transfected cells that expressed high levels of iPLA2beta , retrovirally infected cells were cultured with G418 (0.4 mg/ml) for 1-2 weeks. After G418-resistant colonies became apparent, cell culture was continued for several days. Individual colonies were transferred to a 48-well plate for expansion of clonal cells. Two iPLA2beta -overexpressing (iPLA2-X) lines were obtained that exhibit similar properties not shared by parental cells or clonal lines selected after transfection with empty vector.

Assay of INS-1 Cell iPLA2 Activity-- Seeded INS-1 were washed with phosphate-buffered saline (PBS) and detached by trituration. Cells were collected by centrifugation and disrupted by sonication (Vibra Cell High Intensity Processor, five 1-s pulses, amplitude 12%) in homogenization buffer (250 mM sucrose, 40 mM Tris-HCI, pH 7.1, 4 °C). Homogenates were centrifuged (15,000 × g, 45 min, 4 °C) to yield a cytosolic supernatant. Protein content was measured with Coomassie regent (Pierce) against bovine serum albumin standard. Ca2+-independent PLA2 activity in aliquots of cytosol (25 µg of protein) was assayed by ethanolic injection (5 µl) of 1-palmitoyl-2-[14C]linoleoyl-sn-glycero-3-phosphocholine (final concentration 5 µM) in assay buffer (40 mM Tris, pH 7.5, 5 mM EGTA; total volume 200 µl). Assay mixtures were incubated (3 min, 37 °C, with shaking) and reactions terminated by adding butanol (0.1 ml) and vortexing. After centrifugation (2,000 × g, 5 min), products in the butanol layer were analyzed by silica gel G TLC in petroleum ether/ethyl ether/acetic acid (80/20/1). The TLC plate region containing free fatty acid was identified with iodine vapor and scraped into a scintillation vial. Released [14C]fatty acid was measured by liquid scintillation spectrometry, and PLA2 specific activity was calculated from dpm of released fatty acid and protein content as described (61).

Immunoblotting Analyses of INS-1 Cell iPLA2 Protein-- INS-1 cell cytosolic proteins were analyzed by SDS-PAGE and transferred to a nylon membrane that was subsequently blocked (3 h, room temperature) with Tris-buffered saline plus Tween (TBS-T, 20 mM Tris-HCl, 137 mM NaCl, pH 7.6, 0.05% Tween 20) containing 5% milk protein. The blot was then washed (TBS-T, 5 min, five times) and incubated (1 h, room temperature) with a polyclonal antibody (1:2000 dilution in TBS-T) to iPLA2beta generated by multiple antigen core technology against peptides in the iPLA2beta deduced amino acid sequence, as described below. The nylon membrane was then washed in TBS-T (5 min, five times) and incubated (1 h, room temperature) with a secondary antibody coupled to horseradish peroxidase (Roche Molecular Biochemicals) at 1:40,000 dilution in TBS-T containing 3% BSA. The antibody complex was visualized by enhanced chemiluminescence (ECL, Amersham Pharmacia Biotech).

Determination of Insulin Secretion by INS-1 Insulinoma Cells-- Culture medium from INS-1 cells seeded in 24-well plates was removed, and the cells were washed twice in KRB medium and incubated (1 h, 37 °C, under an atmosphere of 95% air, 5% CO2) in KRB medium (1 ml). Medium was then removed and replaced with KRB medium containing glucose (0-18 mM) with or without forskolin (2.5 µM), IBMX (100 µM), or dibutyryl cAMP (1 mM). In experiments with BEL (10 µM) or propranolol (250 µM), these agents were added both to preincubation medium and to medium for the experimental incubation. After addition of final incubation medium, cells were incubated (1 h, 37 °C) under the atmosphere described above, and medium was then removed for measurement of insulin by radioimmunoassay (62). Cells were then detached from the plate and their acid-ethanol extractable insulin determined by radioimmunoassay (63). Secreted insulin was expressed as a fraction of total cellular insulin content (64).

Determination of INS-1 Cell cAMP Content-- After experimental incubations, medium was removed from each well, and ice-cold ethanol (0.4 ml) containing IBMX (100 µM) was added. After a 5-min room temperature incubation, cells were detached with a rubber policeman, and ethanol and cells were placed in glass test tubes (12 × 75 mm). Cells were sedimented by centrifugation (1500 × g, 10 min), and the supernatant was placed in a clean test tube, concentrated to dryness under nitrogen, and reconstituted in 50 mM phosphate buffer (0.4 ml). The cAMP content was measured by enzyme immunoassay and normalized to cell protein content (65-67).

Incubation of INS-1 Cells with Arachidonic Acid to Induce Phospholipid Remodeling-- INS-1 cells were cultured in RPMI medium containing penicillin, streptomycin, fungizone, and gentamicin (0.1% w/v each). Cells (1.2 × 106/condition) were treated (30 min, 37 °C) with vehicle only or with BEL (10 µM). Medium was then removed and replaced with fresh medium containing no supplements other than those described above or containing arachidonic acid (final concentration 70 µM), and cells were cultured at 37 °C. After 0, 2, 6, 8, or 24 h, cells were washed twice with PBS, suspended in homogenization buffer, and disrupted by sonication. Lipids were extracted (68) and the extract concentrated and analyzed by NP-HPLC.

Chromatographic Analyses of Phospholipids-- Phospholipid head-group classes were separated by NP-HPLC (47) analyses on a silicic acid column (LiChrosphere Si-100 (10 µm, 250 × 4.5 mm); Alltech, Deerfield, IL) with the solvent system hexane, 2-propanol, 25 mM potassium phosphate, pH 7.0, ethanol, acetic acid (367/490/62/100/0.6) at a flow of 0.5 ml/min for 60 min and then 1.0 ml/min. The retention time of standard PC was 102 min.

Electrospray Ionization Mass Spectrometric Analyses of Choline-containing Lipids-- PC species were analyzed as Li+ adducts by ESI/MS on a Finnigan (San Jose, CA) TSQ-7000 triple stage quadrupole mass spectrometer with an ESI source controlled by Finnigan ICIS software. Phospholipids were dissolved in methanol/chloroform (9/1, v/v) containing LiOH (2 nmol/µl), infused (1 µl/min) with a Harvard syringe pump, and analyzed under described conditions (69, 70). For tandem MS, precursor ions selected in the first quadrupole were accelerated (32-36 eV collision energy) into a chamber containing argon (2.3-2.5 millitorr) to induce collisional-activated dissociation, and product ions were analyzed in the final quadrupole to identify PC species in the total ion current profile (70).

Measurement of Nonesterified Arachidonic Acid in INS-1 Cells by Isotope Dilution Gas Chromatography Negative Ion Electron Capture Mass Spectrometry-- Parental and iPLA2beta -overexpressing INS-1 cells that had been incubated with supplemental arachidonic acid for 24 h as described above were washed with 0.1% BSA in KRB four times to remove unincorporated arachidonic acid and were then preincubated for 30 min in KRB medium containing 10 µM BEL or BEL-free vehicle. The precincubation medium was then removed, and the cells were incubated for 1 h at 37 °C in KRB medium containing 0.1% BSA, 2.5 mM CaCl2, and 2 or 11 mM glucose without or with IBMX (100 µM). Incubations were terminated by extraction with 2 ml of chloroform/methanol (1/1) containing 330 pmol of [2H8]arachidonic acid internal standard. Extracts were analyzed by RP-HPLC to isolate arachidonic acid, which was converted to a pentafluorobenzyl ester derivative and analyzed by GC/MS in negative ion electron capture mode (47). Selected monitoring of carboxylate anions of arachidonate (m/z 303) and [2H8]arachidonate (m/z 311) was performed to quantitate arachidonate by reference to a standard curve (47). The amount of arachidonic acid was expressed as a ratio to the lipid phosphorus content of the extract.

Immunocytofluorescence Localization of iPLA2beta within INS-1 Cells-- We prepared an iPLA2beta antibody by multiple antigen core methods (Research Genetics) that link eight peptide copies to an octameric lysine core (71). The iPLA2beta peptides coupled to this core for immunizing rabbits were 25KEVSLADYASSERVRE41 and 489RMKDEVFRGSRPY501. In INS-1 cells that overexpress iPLA2beta , this antibody recognizes an 84-kDa protein corresponding to full-length iPLA2beta (Fig. 1), and recognition of the protein is blocked by including the immunizing peptides in incubations with the antibody. To determine the subcellular location of iPLA2beta , cells were allowed to attach to chambered glass slides overnight and then treated with experimental solutions. At the end of incubations, cells were rinsed in PBS, fixed in 4% paraformaldehyde, washed with PBS, fixed in ice-cold methanol, washed, and blocked in a PBS solution containing globulin-free BSA (1%), Triton X-100 (0.3%), and goat serum (3%). Primary antibodies (either preimmune immunoglobulin or anti-iPLA2beta , 0.003 µg/ml) were then added, and cells were incubated (18 h, 4 °C) in a humidified chamber. Cells were then washed and incubated (1 h, in the dark) with a secondary antibody (affinity-purified goat anti-rabbit IgG, 1:200 dilution) coupled to the fluorophore Cy3. Cells were then washed and covered with Antifade solution (Molecular Probes, Eugene, OR). Slides were mounted with coverslips and examined by confocal microscopy at excitation and emission wavelengths of 550 and 570 nm, respectively.

Statistical Analyses-- Student's t test was used to compare two groups, and multiple groups were compared by one-way analysis of variance with post hoc Newman-Keul's analyses.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Transfection of INS-1 insulinoma cells with a retroviral construct containing the rat iPLA2beta cDNA followed by selection of G418-resistant cells resulted in the isolation of two stably transfected clones that expressed severalfold more iPLA2beta activity than parental INS-1 cells (Fig. 1A). Like the iPLA2beta activity in pancreatic islets and in other insulinoma cell lines (10), the iPLA2beta activity in the stably transfected cells was stimulated by 1 mM ATP and virtually completely inhibited by 10 µM BEL (Fig. 1A). The iPLA2-X cell lines also exhibited an increased content of an 84-kDa protein that was recognized by an iPLA2beta antibody after SDS-PAGE and immunoblotting analyses (Fig. 1B). Increased iPLA2beta expression was a stable property of the transfected cells and persisted on serial passage in culture.


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 1.   Overexpression of iPLA2beta in INS-1 insulinoma cells stably transfected with iPLA2beta cDNA in a retroviral vector. Two clonal INS-1 cell lines were prepared by stable transfection with a retroviral vector containing iPLA2beta cDNA as described under "Experimental Procedures," and levels of their iPLA2beta activity (panel A) and immunoreactive protein (panel B) were compared with those of parental INS-1 cells. PLA2 activity was measured in the absence of Ca2+ and presence of EGTA without (open bars) or with 1 mM ATP alone (cross-hatched bars) or ATP and 10 µM BEL (solid bars). The leftmost set of bars reflects activity from parental cells (control) and the center and rightmost sets of bars reflect activity from the two clonal INS-1 cell lines transfected with iPLA2 cDNA in the retroviral construct (#1-iPLA2-X and #2-iPLA2-X, respectively). Immunoblotting analyses (panel B) were performed after SDS-PAGE analyses of INS-1 cell cytosolic protein. After transfer to nylon membranes, proteins were probed with an iPLA2beta antibody and visualized with ECL as described under "Experimental Procedures." Migration positions of molecular size markers are illustrated at the left margin of panel B, and the three experimental lanes represent immunoreactive proteins from parental INS-1 cells (control) and the two iPLA2beta -overexpressing lines (#1-iPLA2-X and #2-iPLA2-X), respectively. The arrow at the right indicates the expected migration position of an 84-kDa protein corresponding to full-length rat iPLA2beta .

When treated with the adenylyl cyclase activator forskolin (2.5 µM), the iPLA2-X INS-1 cells secreted more insulin than did parental INS-1 cells or INS-1 cells transfected with an empty retroviral construct that did not contain iPLA2beta cDNA (Fig. 2). The magnitude of this effect increased with the medium glucose concentration over the range 0-5 mM. Similar responses to glucose and forskolin were observed with both of the iPLA2-X cell lines (data not shown). Similarly, both of the iPLA2-X cell lines exhibited increased insulin secretory responses, compared with control INS-1 cells, when stimulated with the cAMP phosphodiesterase inhibitor IBMX, and this response also increased with the medium glucose concentration over the range 0-5 mM (Fig. 3). The magnitude of the increased insulin secretory response to glucose was similar when either forskolin or IBMX was used as the cAMP-elevating stimulus, and the combination of forskolin and IBMX induced only slightly greater secretory responses than either agent alone (data not shown).


View larger version (24K):
[in this window]
[in a new window]
 
Fig. 2.   Effects of glucose and the adenylyl cyclase activator forskolin on insulin secretion from iPLA2beta -overexpressing and control INS-1 cells. Insulin secretion was measured after 1-h incubation of INS-1 cells in medium containing 0, 2, or 5 mM glucose without or with 2.5 µM forskolin and normalized to cell insulin content to yield fractional secretion values. Secretory responses were compared among parental INS-1 cells, INS-1 cells transfected with an empty retroviral vector without iPLA2beta cDNA, and stably transfected INS-1 cells that overexpressed iPLA2beta (clone 1 from Fig. 1). Mean fractional secretion values are displayed, and S.E. are indicated (n = 6). Values for forskolin-treated iPLA2-X INS-1 cells were significantly higher (p < 0.05) than those from non-forskolin-treated cells and than those from control cells at all [glucose].


View larger version (29K):
[in this window]
[in a new window]
 
Fig. 3.   Effects of glucose and the cAMP phosphodiesterase inhibitor IBMX on insulin secretion from iPLA2beta -overexpressing and control INS-1 cells. Secretion studies were similar to those in Fig. 2 except that IBMX (0.1 mM) and not forskolin was used to elevate cAMP. Mean fractional secretion values are displayed and S.E. indicated (n = 6). Values for IBMX-treated iPLA2-X cells were significantly higher (p < 0.05) than those for non-IBMX-treated cells and than those for control cells at glucose concentrations of 2 and 5 mM.

Increasing the medium glucose concentration above 5 mM did not further amplify the insulin secretory response to forskolin (Fig. 4A) or IBMX (Fig. 4B) above that achieved with 5 mM glucose and either forskolin or IBMX for iPLA2-X INS-1 cells. Unlike control INS-1 cells, the iPLA2-X cells exhibited enhanced insulin secretion in response to either forskolin or IBMX at 0 or 2 mM glucose. With control cells, secretory responses to forskolin or IBMX required the presence of a glucose concentration exceeding 2 mM, and no increase in secretion was induced by those agents at 0 or 2 mM glucose. Purified native beta -cells isolated by fluorescence-activated cell sorting also fail to secrete insulin in response to glucose alone but exhibit glucose-induced insulin secretion in the presence of cAMP-elevating agents (72), and INS-1 and other insulinoma cell lines exhibit more robust insulin secretory responses to glucose in the presence of cAMP-elevating agents (73, 74).


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 4.   Glucose-concentration dependence of effects of forskolin or IBMX to increase insulin secretion from iPLA2beta -overexpressing and control INS-1 cells. Secretion studies in panels A and B were similar to those in Figs. 2 and 3, respectively, except that glucose concentrations of 8, 11, and 17 mM were also examined. Mean fractional secretion values are displayed and S.E. indicated (n = 6). Values for forskolin- or IBMX-treated iPLA2-X cells were significantly higher (p < 0.05) than those for nontreated cells and than those for control cells at all [glucose].

Both forskolin and IBMX alone and in combination induced an increase in INS-1 cell cAMP content (Fig. 5). Despite the greater insulin secretory responses to cAMP-elevating agents by iPLA2-X cells compared with control INS-1 cells, iPLA2-X cells did not exhibit greater rises in cAMP than control cells when stimulated with forskolin or IBMX. This indicates that augmented cAMP accumulation does not explain enhanced insulin secretion by iPLA2-X cells and suggests that responsiveness of the secretory apparatus to cAMP is increased by iPLA2beta overexpression.


View larger version (31K):
[in this window]
[in a new window]
 
Fig. 5.   Effects of glucose, forskolin, and IBMX on cAMP content of iPLA2beta -overexpressing and control INS-1 cells. The cAMP content was measured by enzyme immunoassay as described under "Experimental Procedures" in parental INS-1 cells (control) or iPLA2beta -overexpressing INS-1 cells (iPLA2-X, clone 1, Fig. 1) that had been incubated for 1 h without or with forskolin (2.5 µM) or IBMX (0.1 mM) alone or in combination. Mean values for cAMP normalized to cellular protein content are displayed, and S.E. are indicated (n = 6).

At a concentration of 10 µM, the iPLA2beta inhibitor BEL (11, 12) attenuated insulin secretion induced by glucose and IBMX from iPLA2-X cells and virtually completely suppressed stimulated insulin secretion from control INS-1 cells (Fig. 6A). Similar effects of BEL were observed with cells stimulated with forskolin and glucose (data not shown). At 10 µM, BEL inhibits iPLA2beta activity in iPLA2-X INS-1 cells by over 95% (Fig. 1). These findings suggest that iPLA2beta participates in acute signaling events involved in induction of insulin secretion by glucose and cAMP-elevating agents. It is of interest that suppression of insulin secretion in response to glucose and cAMP-elevating agents is virtually completely suppressed by BEL in control INS-1 cells but only partially suppressed in iPLA2-X INS-1 cells. This suggests that the history of iPLA2beta overexpression modifies secretory responsiveness in a manner that is not reversed by acute iPLA2beta inhibition.


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 6.   Effects of the iPLA2beta suicide substrate BEL and of the phosphatidate phosphohydrolase inhibitor propranolol on insulin secretion induced by glucose and forskolin or IBMX from control and iPLA2beta -overexpressing INS-1 cells. Panel A, insulin secretion studies were similar to those in Fig. 3, except that the glucose concentration was either 2, 8, or 11 mM, and cells were pre-treated (30 min) with either BEL (10 µM) or with BEL-free vehicle before the experimental incubation. Panel B, insulin secretion studies were similar to those in panel A, except that forskolin (2.5 µM) rather than IBMX (0.1 mM) was used to elevate cAMP, and cells were pre-treated with propranolol (250 µM) or propranolol-free vehicle rather than with BEL before the experimental incubation. Mean fractional secretion values are displayed, and S.E. are indicated (n = 6). BEL-treated cells exhibited significantly (p < 0.05) lower fractional secretion values than non-BEL-treated cells under all tested conditions. Propranolol-treated cells exhibited significantly higher fractional secretion values at 2 and 11 mM glucose for iPLA2-X INS-1 cells.

BEL also inhibits PAPH-1 (55), and effects of BEL are often compared with those of the PAPH inhibitor propranolol to distinguish effects attributable to inhibition of iPLA2beta or to PAPH-1 (47, 75-77). At a concentration that maximally inhibits PAPH in beta -cells (78) and in amniotic WISH cells (76), propranolol did not mimic the effect of BEL to suppress insulin secretion from iPLA2-X or control INS-1 cells induced by forskolin and glucose but tended to amplify the secretory response (Fig. 6B). This is consistent with a report that propranolol amplifies insulin secretion from beta -cells (78). These findings indicate that the suppression by BEL of insulin secretion from iPLA2-X and control INS-1 cells stimulated with glucose and cAMP-elevating agents is not attributable to inhibition of PAPH-1.

Although BEL partially suppresses stimulated insulin secretion from iPLA2-X cells, the fact that BEL-treated iPLA2-X cells continued to secrete more insulin than control INS-1 cells when stimulated with glucose and cAMP-elevating agents (Fig. 6A) suggests that the history of iPLA2beta overexpression altered the secretory responsiveness of the cells in a manner that was not completely reversed by acute inhibition of iPLA2beta activity. It was considered possible that this reflected an effect of iPLA2beta overexpression on INS-1 cell membrane phospholipid composition. Native islet beta -cells are highly enriched in arachidonate-containing phospholipids compared with cells from other tissues, and such phospholipid species may be important in secretion (69). A housekeeping role for iPLA2beta in generating LPC acceptors for arachidonate incorporation into PC in murine P388D1 cells has been suggested from observations that inhibiting iPLA2beta reduces both P388D1 cell LPC levels and [3H]arachidonate incorporation into PC (4, 17, 18). This suggests that iPLA2beta overexpression might cause increases in INS-1 cell arachidonate-containing phospholipids and secretory responsiveness.

To test this possibility, we examined PC molecular species in iPLA2-X cells and in parental INS-1 cells by ESI/MS. Fig. 7A is an ESI/MS spectrum of Li+ adducts of parental INS-1 cell PC species that had been isolated by NP-HPLC, and it is virtually identical to the PC spectrum obtained from iPLA2-X INS-1 cells (Fig. 9A). Major ions in the spectrum represent Li+ adducts of 16:0/16:1-GPC (m/z 738), 16:1/18:1-GPC (m/z 764), 16:0/18:1-GPC (m/z 766), and 18:1/18:1-GPC (m/z 792). The identities of the species represented by these ions were determined by collisionally activated dissociation and tandem MS (70). Arachidonate-containing species at m/z 788 (16:0/20:4-GPC), m/z 816 (18:0/20:4-GPC), or m/z 814 (18:1/20:4-GPC) are not abundant. Adding supplemental arachidonic acid to the culture medium caused the INS-1 cells to remodel their phospholipids in a time-dependent fashion so that the abundance of arachidonate-containing PC species increased. After 6 h, signals for 16:0/20:4-GPC, 18:1/20:4-GPC, and 18:0/20:4-GPC had increased severalfold (Fig. 7B), and by 18 h, 16:0/20:4-GPC had become the most abundant PC species in the mixture (Fig. 7C). The iPLA2-X INS-1 cells incorporated arachidonic acid into PC (Fig. 7D) in a manner similar to that of parental INS-1 cells, and the time course of appearance of arachidonate-containing PC species was virtually identical for iPLA2-X and control INS-1 cells (Fig. 8).


View larger version (41K):
[in this window]
[in a new window]
 
Fig. 7.   Electrospray ionization mass spectrometric analyses of glycerophosphocholine lipid species in iPLA2beta -overexpressing and control INS-1 cells incubated with supplemental arachidonic acid. Control (panels A-C) or iPLA2beta -overexpressing (panel D) INS-1 cells were incubated in medium with supplemental arachidonic acid for 0 h (panel A), 6 h (panel B), or 18 h (panels C and D). Lipids were then extracted and analyzed by NP-HPLC to isolate GPC lipids, which were analyzed by ESI/MS as Li+ adducts. Identities of the GPC lipid species represented by ions in the total ion current profile were determined by collisionally activated dissociation and tandem MS.


View larger version (26K):
[in this window]
[in a new window]
 
Fig. 8.   Time course of appearance of arachidonate-containing GPC lipid species in control and iPLA2beta -overexpressing INS-1 cells incubated with supplemental arachidonic acid. Experiments were performed as in Fig. 7, and ion current intensities at m/z 788 (16:0/20:4-GPC), 816 (18:0/20:4-GPC), and 814 (18:1/20:4-GPC) were expressed as a ratio to that at m/z 766 (16:0/18:1-GPC). Mean values are displayed, and S.E. are indicated (n = 4).

After treatment of beta -cells with BEL, iPLA2beta activity recovers slowly, and there is virtually no measurable activity for 6 h (47). To determine whether iPLA2beta inhibition alters the early time course of arachidonate incorporation into INS-1 cell PC, appearance of arachidonate-containing PC species was compared in non-BEL-treated and in BEL-treated iPLA2-X INS-1 cells (Fig. 9). In non-BEL-treated cells incubated with supplemental arachidonic acid, the abundance of 16:0/20:4-GPC and of 18:0/20:4-GPC increased between time 0 (Fig. 9A) and 2 h of incubation (Fig. 9B) and increased further at 6 h (Fig. 9C). A similar response occurred in BEL-treated iPLA2-X INS-1 cells (Fig. 9D), and the time course of appearance of arachidonate-containing PC species was virtually identical in non-BEL-treated and in BEL-treated iPLA2-X INS-1 cells (Fig. 10). Similar results were obtained with parental INS-1 cells (data not shown). Findings in Figs. 7-10 do not support a role for iPLA2beta in arachidonic acid incorporation into INS-1 cell PC, even under conditions where the enzyme is overexpressed.


View larger version (42K):
[in this window]
[in a new window]
 
Fig. 9.   ESI/MS analyses of glycerophosphocholine lipid species in iPLA2beta -overexpressing INS-1 cells treated with BEL or BEL-free vehicle and then incubated with supplemental arachidonic acid. iPLA2beta -overexpressing INS-1 cells were treated with BEL (panel D) or with BEL-free vehicle (panels A-C) and then incubated in culture medium with supplemental arachidonic acid for 0 h (panel A), 2 h (panel B), or 6 h (panels C and D). Lipids were extracted and analyzed by NP-HPLC and ESI/MS as in Fig. 7.


View larger version (30K):
[in this window]
[in a new window]
 
Fig. 10.   Time course of appearance of arachidonate-containing GPC lipid species in iPLA2beta -overexpressing INS-1 cells that had been treated with BEL or with BEL-free vehicle and then incubated with supplemental arachidonic acid. Experiments were performed as in Fig. 9 and data analyzed as in Fig. 8. Mean values are displayed, and S.E. are indicated (n = 4).

When the nonesterified arachidonate content of iPLA2beta -overexpressing INS-1 cells was measured by isotope dilution GC/MS using [2H8]arachidonic acid as internal standard (Fig. 11), values for cells incubated with 11 mM glucose without or with 100 µM IBMX were 18.9 and 27.1 pmol/nmol of lipid phosphorus, respectively. Nonesterified arachidonate levels were 6.7 pmol/nmol of lipid phosphorus higher for cells incubated with 11 mM glucose than for those incubated with 2 mM glucose, and arachidonate release was suppressed to 27% of control values when the cells were treated with BEL. No net increase in nonesterified arachidonate content was observed for parental INS-1 cells upon increasing the medium glucose concentration or adding IBMX to the incubations, although BEL reduced the basal content of nonesterified arachidonate to 21% of control values.


View larger version (28K):
[in this window]
[in a new window]
 
Fig. 11.   Isotope dilution gas chromatographic mass spectrometric quantitation of nonesterified arachidonate content of iPLA2beta -overexpressing INS-1 cells. Stably transfected iPLA2beta -overexpressing INS-1 cells were treated with BEL-free vehicle (panels A and B) or with 10 µM BEL for 30 min, and medium was then removed. Cells were placed in fresh incubation medium containing glucose at a concentration of 2 mM (panel A) or 11 mM (panels B and C) and incubated for 1 h as under "Experimental Procedures." Incubations were terminated by extraction with 2 ml of chloroform/methanol (1/1) containing 330 pmol of [2H8]arachidonic acid internal standard. Extracts were analyzed by RP-HPLC to isolate arachidonic acid, which was converted to a pentafluorobenzyl ester derivative and analyzed by GC/MS in negative ion electron capture mode. Selected monitoring of carboxylate anions of arachidonate (m/z 303) and [2H8]arachidonate (m/z 311) was performed to quantitate arachidonate by reference to a standard curve. The amount of arachidonic acid was expressed as a ratio to the lipid phosphorus content of the extract.

Several of our findings suggest a role for iPLA2beta in INS-1 cell signaling responses to cAMP-elevating agents. The group IVA PLA2 (cPLA2) has well established signaling functions (5), and, upon cellular activation, cPLA2 associates with nuclear membranes (79-81). To determine whether iPLA2beta might undergo nuclear association during signaling, we examined the subcellular location of the enzyme in iPLA2-X INS-1 cells in immunocytofluorescence studies with an antibody generated (71) against peptides in the iPLA2beta sequence. This antibody recognizes an 84-kDa protein corresponding to full-length iPLA2beta in iPLA2-X INS-1 cells (Fig. 1), and recognition is blocked by including the immunizing peptides in the incubation with the antibody.

Fig. 12 represents an immunocytofluorescence experiment with iPLA2-X INS-1 cells that were incubated, fixed, permeabilized, treated with iPLA2beta antibody or preimmune antibody, treated with fluorophore-coupled secondary antibody, and examined by confocal fluorescence microscopy. Cells incubated with preimmune antibody yield little fluorescence (upper left), and inclusion of immunizing peptides with iPLA2beta antibody also results in little signal (upper right). iPLA2-X INS-1 cells incubated at basal glucose without other stimuli exhibit diffuse cytofluorescence and some faint perinuclear halos (lower left). Treating iPLA2-X INS-1 cells with the cAMP phosphodiesterase inhibitor IBMX induces intense perinuclear fluorescence (lower right), suggesting that iPLA2beta associates with nuclei.


View larger version (62K):
[in this window]
[in a new window]
 
Fig. 12.   Immunocytofluorescence study of iPLA2beta subcellular distribution in iPLA2beta -overexpressing INS-1 cells. iPLA2beta -overexpressing INS-1 cells were allowed to attach to glass slides and incubated in medium that contained 2 mM glucose with 0.1 mM IBMX (lower right panel) or without IBMX (all other panels). Cells were then fixed, permeabilized, and incubated with pre-immune immunoglobulin (upper left) or with iPLA2beta antibody (all other panels) with (upper right) or without (all other panels) iPLA2beta peptides that had been used to generate the antibody. Secondary antibody coupled to the fluorophore Cy3 was added, and slides were examined by confocal immunofluorescence microscopy as described under "Experimental Procedures." pAb, polyclonal antibody.

A consistent finding was that iPLA2beta immunocytofluorescence in IBMX-treated cells was more intense than that observed for untreated cells (Fig. 12). Similar observations have been reported for immunocytofluorescence studies with cPLA2 and with the arachidonate 5-lipoxygenase (79), both of which undergo nuclear association in cells treated with calcium ionophores. Two potential explanations of this phenomenon have been proposed (79). One is that there is a greater loss of soluble than of membrane-associated enzyme during the permeabilization and immunocytofluorescence experiment, and the second is that binding to membranes results in better exposure of the epitope recognized by the antibody. The increase in cytoplasmic fluorescence in such cases has been proposed to reflect association with a cytoplasmic membrane structure, such as the endoplasmic reticulum, that is induced by the stimulus for membrane association (79), and similar considerations may apply to iPLA2beta .

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In the period since the group VIA PLA2 (iPLA2beta ) was cloned in 1997 (8-10), a variety of potential functions for the enzyme have been proposed (17, 18, 22-54), based in large part on effects of inhibiting iPLA2beta activity with the suicide substrate BEL. Although BEL inhibits iPLA2beta at concentrations that do not inhibit activities of Ca2+-dependent PLA2 enzymes of the sPLA2 or cPLA2 families (4, 11-14), BEL also inhibits PAPH-1 (55) and the recently cloned iPLA2gamma (15). Because pharmacologic studies are ambiguous, manipulating iPLA2beta expression by molecular biologic means is an attractive alternative to studying iPLA2beta function. Although suppression of iPLA2beta expression has been achieved with antisense oligonucleotides in murine P388D1 cells (18), these cells express very low levels of iPLA2beta , and antisense approaches have not been effective in cells that express higher levels of the enzyme, such as insulin-secreting beta -cells (47). We have therefore prepared insulinoma cell lines that overexpress iPLA2beta after stable transfection with retroviral constructs containing the iPLA2beta cDNA to study functions of the enzyme.

Two such iPLA2beta -overexpressing cell lines exhibit more robust insulin secretory responses to glucose and cAMP-elevating agents than do parental INS-1 cells or cells transfected with empty retroviral vector that does not contain the iPLA2beta cDNA. This suggests that iPLA2beta participates in beta -cell signaling events involved in insulin secretion, and this is consistent with previous observations (47-54, 82, 83). Synergy between glucose and cAMP-elevating agents in inducing insulin secretion is also a property of native beta -cells isolated from dispersed islet cells by fluorescence-activated cell sorting, and such cells secrete little insulin in response to glucose unless co-stimulated with agents that increase beta -cell cAMP (72). This has been taken to indicate that cAMP is required to support glucose-induced insulin secretion from beta -cells and that paracrine effects of islet alpha -cell-derived glucagon to maintain beta -cell cAMP levels in intact islets are required for glucose-induced insulin secretion in vivo (72). Agents that elevate cAMP are also known to promote glucose-induced insulin secretion from INS-1 cells and other insulinoma cell lines (73, 74).

Increasing beta -cell cAMP also represents the mechanism whereby the neuropeptide pituitary adenylase cyclase activating polypeptide and the gut-derived incretins glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide amplify insulin secretory responses to glucose (67, 84-88), and prolactin-induced increases in beta -cell cAMP participate in up-regulating insulin secretion during islet adaptation to pregnancy (89). In contrast, decreases in beta -cell cAMP participate in suppression of insulin secretion by epinephrine, somatostatin, prostaglandin E2, leptin, and neuropeptide Y (66, 90, 91). The mechanisms whereby cAMP augments insulin secretory responses to glucose include an increase in cytosolic [Ca2+] resulting from Ca2+ entry and mobilization of intracellular Ca2+ stores (84, 92-94), and cAMP also sensitizes the exocytotic apparatus to Ca2+ (93). Activation of Ca2+/calmodulin-dependent cyclic nucleotide phosphodiesterases that degrade cAMP is involved in a feedback loop that limits glucose-induced insulin secretion, and phosphodiesterase inhibitors amplify glucose-induced insulin secretion (95).

It has been reported recently that cAMP restrains beta -cell PLA2 activation and arachidonate release and that this limits potentiation of insulin secretion by cAMP-elevating agents in isolated islets (96). Overexpression of iPLA2beta might over-ride this feedback loop and thereby amplify insulin secretion, although the identity of the lipid signal generated by iPLA2beta action is not clearly established. Secretagogue-induced increases in nonesterified arachidonate content are less robust in INS-1 cells than in intact pancreatic islets (47), and lysophospholipid products have been proposed to mediate effects of iPLA2beta activation in some cells (38, 42). The effect of iPLA2beta overexpression on INS-1 cell secretion involves sensitization of the exocytotic apparatus to cAMP rather than augmentation of cAMP accumulation because iPLA2beta -overexpressing INS-1 cells do not exhibit higher cAMP levels than control cells when treated with an adenylyl cyclase activator or phosphodiesterase inhibitor, even though iPLA2beta -overexpressing cells exhibit more robust insulin secretory responses to such agents in the presence of glucose.

One effect of cAMP-elevating agents in INS-1 cells appears to be to increase nuclear association of iPLA2beta . Association of the group IVA PLA2 (cPLA2) with nuclei and endoplasmic reticulum (ER) also occurs upon cellular stimulation with agents that induce cPLA2 activation (79-81), and a similar subcellular distribution is observed for other enzymes involved in arachidonate metabolism in stimulated cells (81, 97). The iPLA2beta deduced amino acid sequence contains a bipartite nuclear localization sequence (45) (511KREFGEHTKMTDVKKPK527) similar to that in nucleoplasmin and some other nuclear proteins in which two adjacent basic amino acids are followed by a flexible spacer region that precedes a second cluster that contains three basic residues (98, 99). Although this sequence might be expected to promote entry into the nucleus and images in Fig. 12 suggest a perinuclear location of iPLA2beta , ultrastructural studies are required to determine whether iPLA2beta resides on the cytoplasmic or nucleoplasmic face of the nuclear membrane. The ankyrin repeat domain of iPLA2beta could promote association with either face of the membrane.

Nuclear association of iPLA2beta induced by cAMP-elevating agents in INS-1 cells is of interest because glucose promotes both beta -cell insulin secretion and proliferation, and glucose-induced INS-1 cell mitogenesis is cAMP-dependent (100). Because membranes of the nucleus and ER are contiguous (79, 94), perinuclear accumulation of iPLA2beta is consistent with association with a subcellular compartment that is likely to include ER (94), and products of PLA2 action induce Ca2+ release from beta -cell ER (101), which is thought to participate in induction of insulin secretion (102).

Signaling roles for iPLA2beta in other endocrine (22) and secretory (25, 29, 42, 43) events have also been proposed. It is of interest that iPLA2beta is the vastly predominant cytosolic PLA2 activity in brain (24, 34, 35) and that both brain and islets contain electrically active secretory cells that express many common gene products that are not expressed at comparable abundance in other tissues (103). Among other roles that have been proposed for iPLA2beta are generating substrate for eicosanoid synthesis (26, 30, 32, 33), membrane degradation during apoptosis (27, 39), and regulating membrane phosphatidylcholine composition and content (17, 18, 36, 37). The facts that multiple iPLA2beta splice variants exist (23, 31, 44, 45) that form hetero-oligomers with distinct properties (23) and that iPLA2beta is subject to proteolytic processing that alters its activity (39) suggest that products of the iPLA2beta gene might play multiple roles in cell biology that are dependent on the context of cell-type and maturation or stimulation condition.

One of the earliest proposed roles for iPLA2beta is participation in phospholipid remodeling by generating LPC acceptors for arachidonic acid incorporation into phosphatidylcholine (4, 17, 18). This proposal is based on observations in murine P388D1 cells that inhibiting iPLA2beta activity with BEL (17) or an antisense oligonucleotide (18) suppressed [3H]arachidonic acid incorporation into PC and reduced [3H]LPC levels in [3H]choline-labeled cells. This potential housekeeping function of iPLA2beta is of interest in islets because beta -cells exhibit the highest levels of arachidonate-containing phospholipids of any known tissue and because such molecules might participate in insulin secretion (69, 82, 83). Previous studies in islets and insulinoma cells indicated that inhibiting iPLA2beta did not suppress arachidonic acid incorporation into beta -cell PC and reduced LPC levels only slightly (47), and similar findings were obtained with human U937 monocytic cells (77). We re-examined this issue here because it was considered possible that a phospholipid remodeling role of iPLA2beta might be more apparent in cells that overexpress the enzyme. Our ESI/MS measurements indicate, however, that neither iPLA2beta overexpression nor inhibition of iPLA2beta activity affect the rate or extent of incorporation of arachidonic acid into INS-1 cell PC. These and earlier findings (47, 77) argue against a general housekeeping role for iPLA2beta in arachidonate incorporation into phosphatidylcholine.

Our findings are thus more consistent with a signaling rather than a housekeeping role for iPLA2beta in insulin-secreting beta -cells. The observation that overexpressing iPLA2beta in beta -cells amplifies their insulin secretory responses could prove to be useful in beta -cell engineering. Recently, use of modified immunosuppressive regimens has permitted successful transplantation of human islets in seven consecutive patients with insulin-dependent diabetes mellitus, and each patient remained normoglycemic a year after transplantation without exogenous insulin (105, 106). Widespread application of this therapy is precluded by limited availability of donor organs, and beta -cell lines that are engineered to exhibit regulated insulin secretion could represent an alternate source of cells for transplantation (73, 74, 106). beta -Cells with improved secretory responses and other properties have been engineered by introducing genes in viral vectors and by clonal selection strategies (104, 107-110). Identifying additional genes whose products affect beta -cell secretion might permit further progress, and our findings suggest that iPLA2beta gene products might be useful in constructing engineered beta -cell lines.

    ACKNOWLEDGEMENTS

We thank Karen Green and Dr. Jeffrey Saffitz of the Washington University Department of Pathology for assistance with immunocytofluorescence studies, Dr. Matthew Baker of Research Genetics, Inc. for assistance in peptide antigen selection and generation of the iPLA2beta antibody, Dr. Christopher Newgard (University of Texas Southwestern Medical Center, Dallas, TX) for providing the parental INS-1 cell line, and Denise Kampwerth for assistance in preparing the manuscript.

    FOOTNOTES

* This work was supported by National Institutes of Health Grants R37-DK-34388, P41-RR00954, PO1-HL57278, P60-DK20579, and P30-DK56341; by Career Development Award 2-1999-55 (to Z. M.) from the Juvenile Diabetes Foundation; and by a grant from the American Diabetes Association.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Box 8127, Washington University School of Medicine, 660 S. Euclid Ave., St. Louis, MO 63110. Tel.: 314-362-8190; Fax: 314-362-8188; E-mail: jturk@imgate.wustl.edu.

Published, JBC Papers in Press, January 22, 2001, DOI 10.1074/jbc.M010423200

    ABBREVIATIONS

The abbreviations used are: PLA2, phospholipase A2; BEL, bromoenol lactone suicide substrate; BSA, bovine serum albumin; cPLA2, group IV phospholipase A2; ER, endoplasmic reticulum; ESI, electrospray ionization; GC, gas chromatography; GPC, glycerophosphocholine; IBMX, isobutylmethylxanthine; iPLA2beta , group VIA phospholipase A2; iPLA2gamma , group VIB phospholipase A2, MS, mass spectrometry; NP-HPLC, normal phase high performance liquid chromatography; PAPH, phosphatidate phosphohydrolase; PAGE, polyacrylamide gel electrophoresis; PBS, phosphate-buffered saline; PC, phosphatidylcholine; RP-HPLC, reverse phase high performance liquid chromatography; sPLA2, secretory phospholipase A2; TLC, thin layer chromatography; TBS-T, Tris-buffered saline with Tween 20; LPC, lysophosphatidylcholine.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Dennis, E. A. (1994) J. Biol. Chem. 269, 13057-13060[Free Full Text]
2. Gijon, M. A., and Leslie, C. C. (1997) Semin. Cell Dev. Biol. 8, 297-303[CrossRef][Medline] [Order article via Infotrieve]
3. Dennis, E. A. (1997) Trends Biochem. Sci. 22, 1-2[CrossRef][Medline] [Order article via Infotrieve]
4. Balsinde, J., and Dennis, E. A. (1997) J. Biol. Chem. 272, 16069-16072[Free Full Text]
5. Leslie, C. C. (1997) J. Biol. Chem. 272, 16709-16712[Free Full Text]
6. Tischfield, J. A. (1997) J. Biol. Chem. 272, 17247-17250[Free Full Text]
7. Stafforini, D. M., McIntyre, T. M., Zimmerman, G. A., and Prescott, S. M. (1997) J. Biol. Chem. 272, 17895-17898[Free Full Text]
8. Tang, J., Kriz, R. W., Wolfman, N., Shaffer, M., Seehra, S., and Jones, S. (1997) J. Biol. Chem. 272, 8567-8575[Abstract/Free Full Text]
9. Balboa, M. A., Balsinde, J., Jones, S., and Dennis, E. A. (1997) J. Biol. Chem. 272, 8576-8590[Abstract/Free Full Text]
10. Ma, Z., Ramanadham, S., Kempe, K., Chi, X. S., Ladenson, J. L., and Turk, J. (1997) J. Biol. Chem. 272, 11118-11127[Abstract/Free Full Text]
11. Hazen, S. L., Zupan, L. A., Weiss, R. H., Getman, D. P., and Gross, R. W. (1991) J. Biol. Chem. 266, 7227-7232[Abstract/Free Full Text]
12. Zupan, L. A., Weiss, R. H., Hazen, S., Parnas, B. L., Aston, K. W., Lennon, P. J., Getman, D. P., and Gross, R. W. (1993) J. Med. Chem. 36, 95-100[Medline] [Order article via Infotrieve]
13. Balsinde, J., and Dennis, E. A. (1996) J. Biol. Chem. 271, 6758-6765[Abstract/Free Full Text]
14. Ma, Z., Ramanadham, S., Hu, Z., and Turk, J. (1998) Biochim. Biophys. Acta 1391, 384-400[Medline] [Order article via Infotrieve]
15. Mancuso, D. J., Jenkins, C. M., and Gross, R. W. (2000) J. Biol. Chem. 275, 9937-9945[Abstract/Free Full Text]
16. Tanaka, H., Takeya, R., and Sumimoto, H. (2000) Biochem. Biophys. Res. Commun. 272, 320-326[CrossRef][Medline] [Order article via Infotrieve]
17. Balsinde, J., Bianco, I. D., Ackerman, E. J., Conde-Friebos, K., and Dennis, E. A. (1995) Proc. Natl. Acad. Sci. U. S. A. 92, 8527-8531[Abstract]
18. Balsinde, J., Balboa, M. A., and Dennis, E. A. (1997) J. Biol. Chem. 272, 29317-29321[Abstract/Free Full Text]
19. Lands, W. E. M., and Crawford, C. G. (1976) in The Enzymes of Biological Membranes (Martonosi, A., ed), Vol. 2 , pp. 3-85, Plenum Press, New York
20. Chilton, F. H., Fonteh, A. N., Suarette, M. E., Triggiani, M., and Winkler, J. D. (1996) Biochim. Biophys. Acta 1299, 1-15[Medline] [Order article via Infotrieve]
21. Dennis, E. A. (1992) Methods Enzymol. 209, 1-4[Medline] [Order article via Infotrieve]
22. Derrickson, B. H., and Mandel, L. J. (1997) Am. J. Physiol. 272, F781-F788[Abstract/Free Full Text]
23. Larsson, P. K. A., Claesson, H. E., and Kennedy, B. P. (1998) J. Biol. Chem. 273, 207-214[Abstract/Free Full Text]
24. Molloy, G. Y., Rattray, M., and Williams, R. J. (1998) Neurosci. Lett. 258, 139-142[CrossRef][Medline] [Order article via Infotrieve]
25. Alzola, E., Perez-Etxebarria, A., Kabre, E., Fogarty, D. J., Metioui, M., Chaib, N., Macarulla, J. M., Matute, C., Dehaye, J. P., and Marino, A. (1998) J. Biol. Chem. 273, 30208-30127[Abstract/Free Full Text]
26. Larsson Forsell, P. K. A., Runarsson, G., Ibrahim, M., Bjorkholm, M., and Claesson, H. E. (1998) FEBS Lett. 434, 295-299[CrossRef][Medline] [Order article via Infotrieve]
27. Atsumi, G. I., Tajima, M., Hadano, A., Nakatani, Y., Murakami, M., and Kudo, I. (1998) J. Biol. Chem. 273, 13870-13877[Abstract/Free Full Text]
28. Zhou, Y. P., Teng, D., Drayluk, F., Ostrega, D., Roe, M. W., Philipson, L., and Polonsky, K. S. (1998) J. Clin. Invest. 101, 1623-1632[Abstract/Free Full Text]
29. Tithof, P. K., Peters-Golden, M., and Ganey, P. E. (1998) J. Immunol. 160, 953-960[Abstract/Free Full Text]
30. Akiba, S., Hayama, M., and Sato, T. (1998) FEBS Lett. 437, 225-228[CrossRef][Medline] [Order article via Infotrieve]
31. Larsson Forsell, P. K. A., Kennedy, B. P., and Claesson, H. E. (1999) Eur. J. Biochem. 262, 575-585[Abstract/Free Full Text]
32. Murakami, M., Kambe, T., Shimbara, S., and Kudo, I. (1999) J. Biol. Chem. 274, 3103-3115[Abstract/Free Full Text]
33. Akiba, S., Mizunga, S., Kume, K., Hayama, M., and Sato, T. (1999) J. Biol. Chem. 274, 19906-19912[Abstract/Free Full Text]
34. Yang, H. C., Mosior, M., Ni, B., and Dennis, E. A. (1999) J. Neurochem. 73, 1278-1287[CrossRef][Medline] [Order article via Infotrieve]
35. Yang, H. C., Mosior, M., Johnson, C. A., Chen, Y., and Dennis, E. A. (1999) Anal. Biochem. 269, 278-288[CrossRef][Medline] [Order article via Infotrieve]
36. Baburina, I., and Jackowski, S. (1999) J. Biol. Chem. 274, 9400-9408[Abstract/Free Full Text]
37. Barbour, S. E., Kapur, A., and Deal, C. L. (1999) Biochim. Biophys. Acta 1439, 77-78[Medline] [Order article via Infotrieve]
38. Paget, C., Rey, A., Lafontan, M., Valet, P., and Saulnier-Blache, J. S. (1999) Biochem. Biophys. Res. Commun. 265, 572-576[CrossRef][Medline] [Order article via Infotrieve]
39. Atsumi, G. I., Murakami, M., Kojima, K., Hadano, A., Tajima, M., and Kudo, I. (2000) J. Biol. Chem. 275, 18248-18258[Abstract/Free Full Text]
40. Olivero, J., and Ganey, P. E. (2000) Toxicol. Appl. Pharmacol. 163, 9-16[CrossRef][Medline] [Order article via Infotrieve]
41. Nofer, J. R., Junker, R., Walter, M., Seedorf, U., Assman, G., Zidek, W., and Tepel, M. (2000) Arch. Biochem. Biophys. 374, 213-221[CrossRef][Medline] [Order article via Infotrieve]
42. Isenovic, E., and LaPointe, M. C. (2000) Hypertension 35, 249-254[Abstract/Free Full Text]
43. Wakev, I., Klein, J., Husman, M., Valeva, A., Strauch, S., Wirtz, H., Weichel, O., and Bhakdi, S. (2000) J. Immunol. 164, 5120-5124[Abstract/Free Full Text]
44. Ma, Z., Wang, X., Nowatzke, W., Ramanadham, S., and Turk, J. (1999) J. Biol. Chem. 274, 9607-9616[Abstract/Free Full Text]
45. Ma, Z. & Turk, J. (2001) Progr. Nucleic Acid Res. Mol Biol. 67, in press
46. Nowatzke, W., Ramanadham, S., Hsu, F. F., Ma, Z., Bohrer, A., and Turk, J. (1998) Endocrinology 139, 4073-4085[Abstract/Free Full Text]
47. Ramanadham, S., Hsu, F.-F., Bohrer, A., Ma, Z., and Turk, J. (1999) J. Biol. Chem. 274, 13915-13927[Abstract/Free Full Text]
48. Owada, S., Larsson, O., Arkhammar, P., Katz, A. I., Chibalin, A. V., Berggren, P. O., and Bertorello, A. M. (1999) J. Biol. Chem. 274, 200-2008
49. Simonsson, E., Karlsson, S., and Ahren, B. (1998) Diabetes 47, 1436-1443[Abstract]
50. Simonsson, E., and Ahren, B. (2000) Int. J. Pharmacol. 27, 1-11
51. Thams, P., and Capito, K. (1997) Biochem. Pharm. 53, 1077-1086[CrossRef][Medline] [Order article via Infotrieve]
52. Ramanadham, S., Gross, R. W., Han, X., and Turk, J. (1993) Biochemistry 32, 337-346[Medline] [Order article via Infotrieve]
53. Turk, J., Gross, R. W., and Ramanadham, S. (1993) Diabetes 42, 367-374[Abstract]
54. Ramanadham, S., Wolf, M., Li, B., Bohrer, A., and Turk, J. (1997) Biochim. Biophys. Acta 1344, 153-164[Medline] [Order article via Infotrieve]
55. Balsinde, J., and Dennis, E. A. (1996) J. Biol. Chem. 271, 31937-31941[Abstract/Free Full Text]
56. Frodin, M., Sekine, N., Roche, E., Fillous, C., Prentki, M., Wollheim, C. B., and Obberghen, E. V. (1995) J. Biol. Chem. 270, 7882-7889[Abstract/Free Full Text]
57. Assimacopoulos-Jeannett, F., Thumelin, S., Roche, E., Esser, V., McGarry, J. D., and Prentki, M. (1997) J. Biol. Chem. 272, 1659-1664[Abstract/Free Full Text]
58. Sekine, N., Fasolato, C., Pralong, W. F., Theler, J.-M., and Wollheim, C. B. (1997) Diabetes 46, 1424-1433[Abstract]
59. Coffin, J. M., and Varmus, H. E. (1996) Retrovirus , Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY
60. Morgenstern, J. P., and Land, H. (1990) Nucleic Acids Res. 18, 3587-3590[Abstract]
61. Gross, R. W., Ramanadham, S., Kruszka, K., Han, X., and Turk, J. (1993) Biochemistry 32, 327-336[Medline] [Order article via Infotrieve]
62. Ramanadham, S., Hsu, F.-F, Zhang, S., Bohrer, A., Ma, Z., and Turk, J. (2000) Biochim. Biophys. Acta 1484, 251-266[Medline] [Order article via Infotrieve]
63. Ma, Z., Ramanadham, S., Corbett, J., Bohrer, A., Gross, R. W., McDaniel, M. L., and Turk, J. (1996) J. Biol. Chem. 271, 1029-1042[Abstract/Free Full Text]
64. Xu, G. G., Gao, Z., Borge, P. D., and Wolf, B. A. (1999) J. Biol. Chem. 274, 18067-18074[Abstract/Free Full Text]
65. Turk, J., Mueller, M., Bohrer, A., and Ramanadham, S. (1992) Biochim. Biophys. Acta 1125, 280-291[Medline] [Order article via Infotrieve]
66. Ahren, B., and Havel, P. J. (1999) Am. J. Physiol. 277, R959-R966[Abstract/Free Full Text]
67. Flamzes, D., Gilon, P., Moens, K., Van Breusegem, A., Delmeire, D., Scrocchi, L. A., Henquin, J. C., Drucker, D. J., and Schuit, F. (1999) Diabetes 48, 1979-1986[Abstract]
68. Bligh, E. G., and Dyer, W. J. (1959) Can. J. Biochem. Physiol. 37, 911-917
69. Ramanadham, S., Hsu, F.-F., Bohrer, A., Nowatzke, W., Ma, Z., and Turk, J. (1998) Biochemistry 37, 4553-4567[CrossRef][Medline] [Order article via Infotrieve]
70. Hsu, F.-F., Bohrer, A., and Turk, J. (1998) J. Am. Soc. Mass Spectrom. 9, 516-526[CrossRef][Medline] [Order article via Infotrieve]
71. Basak, A., Boudreault, A., Chen, A., Chretien, M., Seidah, N. G., and Lazure, C. (1995) J. Pept. Sci. 6, 385-395
72. Pipeleers, D. G., Schuit, F. C., in't Veld, P. A., Maes, E., Hoogh-Peters, E. L., Van De Winkel, M., and Gepts, W. (1985) Endocrinology 117, 824-833[Abstract]
73. Hohmeier, H. E., Mulder, H., Chen, G., Henkel-Rieger, R., Prentki, M., and Newgard, C. B. (2000) Diabetes 49, 424-430[Abstract]
74. Poitout, V., Olson, L. K., and Robertson, R. P. (1996) Diabetes Metab. 22, 7-14[Medline] [Order article via Infotrieve]
75. Balsinde, J., and Dennis, E. A. (1996) Eur. J. Biochem. 235, 480-485[Abstract]
76. Balboa, M. A., Balsinde, J., and Dennis, E. A. (1998) J. Biol. Chem. 273, 7684-7690[Abstract/Free Full Text]
77. Hsu, F.-F., Ma, Z., Wohltmann, M., Bohrer, A., Nowatzke, W., Ramanadham, S., and Turk, J. (2000) J. Biol. Chem. 275, 16579-16589[Abstract/Free Full Text]
78. Metz, S. A., and Dunlop, M. (1991) Biochem. Pharmacol. 41, R1-R4[CrossRef][Medline] [Order article via Infotrieve]
79. Schievella, A. R., Regier, M. K., Smith, W. L., and Lin, L. L. (1995) J. Biol. Chem. 270, 30749-30754[Abstract/Free Full Text]
80. Peters-Golden, M., Song, K., Marshall, T., and Brock, T. (1996) Biochem. J. 318, 797-803[Medline] [Order article via Infotrieve]
81. Gijon, M. A., Spencer, D. M., Kaiser, A. L., and Leslie, C. C. (1999) J. Cell Biol. 145, 1219-1232[Abstract/Free Full Text]
82. Ramanadham, S., Bohrer, A., Mueller, M., Jett, P., Gross, R. W., and Turk, J. (1993) Biochemistry 32, 5339-5351[Medline] [Order article via Infotrieve]
83. Ramanadham, S., Bohrer, A., Gross, R. W., and Turk, J. (1993) Biochemistry 32, 13499-13509[Medline] [Order article via Infotrieve]
84. Leech, C. A., and Haebner, J. F. (1997) J. Biol. Chem. 272, 17987-17993[Abstract/Free Full Text]
85. Suga, S., Kanno, T., Nakano, K., Takeo, T., Dobashi, Y., and Wakui, M. (1997) Diabetes 46, 1755-1760[Abstract]
86. Filipsson, K., Karlsson, S., and Ahren, B. (1998) J. Biol. Chem. 273, 32602-32607[Abstract/Free Full Text]
87. Jamen, F., Persson, K., Bertrand, G., Rodriguez-Henche, N., Puech, R., Bockaert, J., Ahren, B., and Brabet, P. (2000) J. Clin. Invest. 105, 1307-1315[Abstract/Free Full Text]
88. Ahren, B., and Pacini, G. (1999) Am. J. Physiol. 277, E996-E1004[Abstract/Free Full Text]
89. Weinhaus, A. J., Bhagroo, N. V., Brelje, T. C., and Sorenson, R. L. (1998) Diabetes 47, 1426-1435[Abstract]
90. Sequist, E. R., Walseth, T. F., Redmon, J. B., and Robertson, R. P. (1994) J. Lab. Clin. Med. 123, 338-345[Medline] [Order article via Infotrieve]
91. Morgan, D. G., Kulkarni, R. N., Hurley, J. D., Wang, Z. L., Wang, R. M., Ghatei, M. A., Karlsen, A. E., Bloom, S. R., and Smith, D. M. (1998) Diabetologia 41, 1482-1491[CrossRef][Medline] [Order article via Infotrieve]
92. Yackura, K., Kakein, M., and Yada, T. (1996) Diabetes 45, 295-301[Abstract]
93. Ammala, C., Ashcroft, F. M., and Rorsman, P. (1993) Nature 363, 356-358[CrossRef][Medline] [Order article via Infotrieve]
94. Holz, G. G., Leech, C. A., Heller, R. S., Castonguay, M., and Haebner, J. F. (1999) J. Biol. Chem. 274, 14147-14156[Abstract/Free Full Text]
95. Han, P., Werber, J., Surana, M., Fleischer, N., and Michaeli, T. (1999) J. Biol. Chem. 274, 22337-22344[Abstract/Free Full Text]
96. Simonsson, E., Karlsson, S., and Ahren, B. (2000) Biochem. Biophys. Res. Commun. 269, 242-246[CrossRef][Medline] [Order article via Infotrieve]
97. Pouliot, M., McDonald, P. P., Krump, E., Mancini, J. A., McColl, J. A., Weech, P. K., and Borgeat, P. (1996) Eur. J. Biochem. 238, 250-258[Abstract]
98. Robbins, J., Dilworth, S. M., Laskey, R. A., and Dingwall, C. (1991) Cell 64, 615-623[Medline] [Order article via Infotrieve]
99. Dingwall, C., and Laskey, R. A. (1991) Trends Biochem. Sci. 16, 478-481[CrossRef][Medline] [Order article via Infotrieve]
100. Hugl, S. F., White, M. F., and Rhodes, C. J. (1998) J. Biol. Chem. 273, 17771-17779[Abstract/Free Full Text]
101. Wolf, B., Turk, J., Sherman, W., and McDaniel, M. (1986) J. Biol. Chem. 261, 3501-3510[Abstract/Free Full Text]
102. Dukes, I. D., Roe, M. W., Worley, J. F., and Philipson, L. H. (1997) Curr. Opin. Endocrinol. Diabetes 4, 262-271
103. Atouf, F., Czernichow, P., and Scharfman, R. (1997) J. Biol. Chem. 272, 1929-1934[Abstract/Free Full Text]
104. Noel, R. J., Antinozzi, P. A., McGarry, D. J., and Newgard, C. B. (1997) J. Biol. Chem. 272, 18621-18627[Abstract/Free Full Text]
105. Shapiro, A. M. J., Lakey, J. R. T., Ryan, E. A., Korbutt, G. S., Toth, E., Warnock, G. L., Kneteman, N. M., and Rajotte, R. V. (2000) N. Engl. J. Med. 343, 230-238[Abstract/Free Full Text]
106. Robertson, R. P. (2000) N. Engl. J. Med. 343, 289-290[Free Full Text]
107. Hughes, S. D., Johnson, J. H., Quaade, C., and Newgard, C. B. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 688-692[Abstract]
108. Becker, T. C., BeltrandelRio, H., Noel, R. J., Johnson, J. H., and Newgard, C. B. (1994) J. Biol. Chem. 269, 21234-21238[Abstract/Free Full Text]
109. Clark, S. A., Quaade, C., Constandy, H., Hansen, P., Halban, P., Ferber, S., Newgard, C. B., and Normington, K. (1997) Diabetes 46, 958-967[Abstract]
110. Hohmeier, H. E., BeltrandelRio, H., Clark, S. A., Henkel-Reiger, R., Normington, K., and Newgard, C. B. (1997) Diabetes 46, 968-977[Abstract]


Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.